Lite Strategy (LITS) Stock Price, News & Analysis

Company Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.03 to $2.22
• 50-Day Range: N/A
• 52-Week Range: $1.46 to $9.00
• Volume: 650,709 shs
• Average Volume: 598,048 shs
• Market Capitalization: $78.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

LITS Stock Analysis - Frequently Asked Questions

How have LITS shares performed this year?

Lite Strategy's stock was trading at $2.80 at the beginning of 2025. Since then, LITS stock has decreased by 23.6% and is now trading at $2.14.

How do I buy shares of Lite Strategy?

Shares of LITS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LITS
• CIK: 1262104
• Web: N/A
• Phone: (858) 369-7100
• Fax: 302-655-5049
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.70%
• Return on Assets: -60.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.50
• Quick Ratio: 13.50

Sales & Book Value

• Annual Sales: $65.30 million
• Price / Sales: 1.20
• Cash Flow: $5.37 per share
• Price / Cash Flow: 0.41
• Book Value: $4.96 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 35,650,000
• Free Float: 34,543,000
• Market Cap: $78.43 million
• Optionable: N/A
• Beta: 0.36